Brought to you by 
Nycomed takes on European rights to NPS's Preos; all rights later returned
20 Mar 2013
Executive Summary
NPS Pharmaceuticals has licensed Nycomed Holding AS development and marketing rights to the osteoporosis drug Preos in Europe, the Commonwealth of Independent States, and Turkey.
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Specialty Pharmaceuticals
Deal Status
- Terminated
Deal Type
-
Alliance
- Includes Contract
- Includes Equity
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Nycomed takes on European rights to NPS's Preos; all rights later returned
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice